EADV 2025: Psoriasis Treatment and Work Productivity Outcomes
At EADV 2025, Kåre Steinar Tveit, MD, Senior Consultant at Haukeland University Hospital in Bergen, Norway, presented results from the TRIBUTE study on tildrakizumab in patients with moderate to severe psoriasis. The study examined how clinical improvements in pain, itch and DLQI were linked to increased work productivity, using data from Italy and Spain adapted to a Norwegian context.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
